TW200605895A - Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor - Google Patents

Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor

Info

Publication number
TW200605895A
TW200605895A TW094126955A TW94126955A TW200605895A TW 200605895 A TW200605895 A TW 200605895A TW 094126955 A TW094126955 A TW 094126955A TW 94126955 A TW94126955 A TW 94126955A TW 200605895 A TW200605895 A TW 200605895A
Authority
TW
Taiwan
Prior art keywords
inhibitor
combination
pdev
noradrenaline reuptake
selective noradrenaline
Prior art date
Application number
TW094126955A
Other languages
Chinese (zh)
Inventor
Bernadette Hughes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200605895A publication Critical patent/TW200605895A/en

Links

Abstract

The present invention relates to a combination of a selective noradrenaline reuptake inhibitor (NRI) and a phosphodiesterase type 5 (PDEV) inhibitor. Such a combination is particularly useful in the treatment of pain.
TW094126955A 2004-08-10 2005-08-09 Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor TW200605895A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0417777A GB0417777D0 (en) 2004-08-10 2004-08-10 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
TW200605895A true TW200605895A (en) 2006-02-16

Family

ID=33017233

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094126955A TW200605895A (en) 2004-08-10 2005-08-09 Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor

Country Status (5)

Country Link
CN (1) CN101001630A (en)
AR (1) AR052522A1 (en)
GB (1) GB0417777D0 (en)
TW (1) TW200605895A (en)
ZA (1) ZA200700129B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114903997A (en) * 2022-07-13 2022-08-16 北京大学第三医院（北京大学第三临床医学院） Application of iron death inhibitor in preparation of medicine for preventing and treating male reproductive dysfunction

Also Published As

Publication number Publication date
GB0417777D0 (en) 2004-09-15
AR052522A1 (en) 2007-03-21
CN101001630A (en) 2007-07-18
ZA200700129B (en) 2008-07-30

Similar Documents

Publication Publication Date Title
WO2006016262A8 (en) Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor
HK1106131A1 (en) Mitotic kinesin inhibitors and methods of use thereof
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
TNSN06022A1 (en) Use of calcitonin in osteoarthritis
HK1080467A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
WO2005117979A3 (en) Use of il-17 in the treatment of fertility-related disorders
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
IL158738A0 (en) Novel use of 2-phenyl-substituted imidazotriazinones
EP1940377A4 (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
MXPA03007653A (en) Use of lp82 to treat hematopoietic disorders.
MXPA05011699A (en) Agents for the treatment of lower abdominal disorders.
GB0612026D0 (en) New use
TW200605895A (en) Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor
MXPA05010800A (en) Hydroxamic acids useful in the treatment of hyper-proliferative disorders.
IL181183A (en) Use of an elastase inhibitor in the manufacture of a medicament for the treatment of leukemia
TW200642688A (en) New use of PDE7 inhibitors
MXPA05012605A (en) Compositions comprising gastrin compounds and their use in diabetes.
AU2003272390A8 (en) Ampds as modifiers of the p21 pathway and methods of use
YU11904A (en) Use of il-18 inhibitors in hypersensitivity disorders
AU302730S (en) Bed
EA200600531A1 (en) COMBINATION OF SEROTONIN AND LOXAPINE REVERSE CAPTURE INHIBITOR
IL177062A0 (en) Use of 14, 15 - dihydro- 20,21 - dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disorders
AU2003251826A8 (en) Mp21s as modifiers of the p21 pathway and methods of use
EP1534852A4 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE